The company's shares dropped because it will require financing to help launch its first marketed product.
These two healthcare stocks have crushed the broader markets this year.
Verrica held Type A meeting with the FDA regarding the path forward for the resubmission and potential approval of the NDA for VP-102 for the treatment of...
/PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Verrica Pharmaceuticals, Inc....
/PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Verrica Pharmaceuticals...
Attorney Advertising-Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (NASDAQ:...
Corcept's (CORT) earnings miss estimates in second-quarter 2022 while revenues beat the same. Shares down.
Zoetis' (ZTS) earnings miss estimates in second-quarter 2022. The revenues beat estimates owing to the strong uptake of the company's companion animal portfolio products.
Pacira's (PCRX) earnings and revenues fall shy of estimates in the second quarter of 2022.
The Law Offices of Frank R. Cruz reminds investors of the upcoming August 5, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Verrica Pharmaceuticals...